國家衛生研究院 NHRI:Item 3990099045/12353
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 856851      線上人數 : 937
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/12353


    題名: Development of a 2-in-1 vaccine for dengue and measles by a recombinant measles virus expressing tetravalent dengue envelope protein domain III
    作者: Pan, CH;Lin, TH;Hsiao, YJ;Yen, JY
    貢獻者: National Institute of Infectious Diseases and Vaccinology
    摘要: Dengue virus (DENV) infection has a major impact on global public health and current vaccine application is restricted in some countries and only recommended for children older than 9 years. In this study, we have demonstrated that a recombinant measles virus (MV) carried dengue envelope protein domain III (ED3) genes could infect and replicate in the susceptible transgenic mice expressing MV receptor human CD46. After the MV-vectored dengue vaccine immunization, mice developed specific interferon-gamma responses to MV and DENV. Between 4 serotypes of DENV, a dominant DENV-3-specific T-cell response was observed, possibly due to more T-cell epitopes located in DENV-3 ED3 than other serotypes. Neutralizing antibodies against MV and DENV were also induced in the MV-vectored dengue vaccine immunized mice, and protective levels of FRNT50>10 were detected to all serotypes of DENV. We also evaluated the protection against dengue infection. After inoculation with DENV-2, a detectable but significant lower viremia was observed in MV-vectored dengue vaccine immunized mice versus the vector control. In addition, the inflammatory cytokines associated with severe dengue were also significant lower in MV-vectored dengue vaccine immunized mice. Our results with regard to immunogenicity and protection in murine model provide clues for the future application of a 2-in-1 vaccine to against both measles and dengue.
    日期: 2019-10
    關聯: European Journal of Immunology. 2019 Oct;49(S3):1051.
    Link to: https://doi.org/10.1002/eji.201970400
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0014-2980&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000490026903276
    顯示於類別:[潘建雄] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000490026903276.pdf515KbAdobe PDF326檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋